ストックスクリーナーアプリを入手
35.53
5.34%
1.80
アフターアワーズ：
35.53
前日終値:
$33.73
開ける：
$33.89
24時間の取引高:
21.01M
Relative Volume:
1.95
時価総額：
$13.67B
収益：
$5.06B
当期純損益:
$-2.22B
株価収益率:
-6.1048
EPS:
-5.82
ネットキャッシュフロー:
$-3.96B
1週間 パフォーマンス:
+7.70%
1か月 パフォーマンス:
-1.00%
6か月 パフォーマンス:
-59.00%
1年 パフォーマンス:
-59.44%
1日の値動き範囲:
$33.18
$35.97
1週間の範囲:
$32.04
$36.98
52週間の値動き範囲:
$29.25
$170.47
Moderna Inc Stock (MRNA) Company Profile
MRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
35.53 | 13.67B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China - Yahoo Finance
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Trading Up 8.8%Time to Buy? - MarketBeat
Moderna (NASDAQ:MRNA) Trading Down 7.9% Following Analyst Downgrade - MarketBeat
Moderna, Novavax rise as new bat coronavirus identified in China - MSN
Moderna stock rises amid new virus concerns By Investing.com - Investing.com Australia
Analyst calls of the week: Rivian, Block, Moderna, Bumble... - Proactive Investors USA
Moderna, Inc. SEC 10-K Report - TradingView
Rx Rundown: Moderna, Sanofi, GSK and more - MM+M Online
Meitav Investment House Ltd. Sells 184,043 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release? - MSN
Moderna, Inc. to Host Earnings Call - ACCESS Newswire
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Baillie Gifford & Co. Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNA - ACCESS Newswire
Moderna (NASDAQ:MRNA) Price Target Lowered to $78.00 at UBS Group - MarketBeat
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - Nasdaq
Moderna (MRNA) Expected to Announce Earnings on Thursday - MarketBeat
Intrinsic Value Partners LLC Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna's (MRNA) "Sector Perform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now? - MSN
EMA Urged Pfizer And Moderna To Boost Production Volume Of COVID Vax - BW Healthcare World
UBS Adjusts Moderna Price Target to $78 From $96, Maintains Buy Rating -February 19, 2025 at 10:21 am EST - Marketscreener.com
Why Moderna (MRNA) Went Up on Tuesday? - Yahoo Finance
Moderna: A Generational Opportunity for Investors in 2025 - MarketBeat
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health - Quantisnow
Moderna (NASDAQ:MRNA) Stock Rating Lowered by Barclays - MarketBeat
Moderna price target lowered to $78 from $96 at UBS - TipRanks
Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom - BioSpace
Barclays Downgrades Moderna (WBAG:MRNA) - Nasdaq
Rep. Julie Johnson Sells Moderna, Inc. (NASDAQ:MRNA) Shares - MarketBeat
Louisiana State Employees Retirement System Sells 30,100 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Q4 2024 Earnings Call Transcript - MSN
Barclays Downgrades Moderna (MRNA) - MSN
Barclays Downgrades Moderna (BIT:1MRNA) - Nasdaq
Moderna Downgraded by Barclays as Policy Risks and Weak Revenue Weigh on Outlook - GuruFocus.com
Why Moderna (MRNA) Stock Is Up Today By Stock Story - Investing.com Canada
Moderna's Stock Increases by 11.8% Despite Market ChallengesNews and Statistics - IndexBox, Inc.
MRNA: Moderna Stock Rises on Financial Results Despite Downgrade - GuruFocus.com
Moderna rises 8% even as Barclays downgrades - Seeking Alpha
Moderna shares move higher as investors look beyond Q4 losses - Proactive Investors UK
Why Moderna (MRNA) Stock Is Up Today - Financial Content
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges - Benzinga
Moderna has limited upside: Barclays By Investing.com - Investing.com Canada
Market movers: Intel, Moderna, Aftermath Silver, EnWave... - Proactive Investors USA
This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Is Moderna Stock A Buy As Its CEO Fends Off RFK Jr. Concerns? - Yahoo
Barclays Downgrades Moderna to Equalweight From Overweight, Adjusts Price Target to $45 From $111 - Marketscreener.com
Moderna’s Financial Challenges and Pipeline Setbacks Prompt ‘Sell’ Rating by Analyst Tim Anderson - TipRanks
Barclays Downgrades Moderna (MRNA) to Equalweight - StreetInsider.com
Lipid-Nanoparticle Based Genomic Medicines Market Key Players - openPR
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):